John S. McBride serves as Director of the Company. Mr. McBride currently serves as the Chief Financial Officer of Cadent Therapeutics, Inc. Mr. McBride served as Tokai’s Chief Operating Officer from February 2014 to May 2017 and as Tokai’s Chief Financial Officer from September 2016 to May 2017. He previously served as Tokai’s interim Chief Financial Officer from April 2014 until September 2014. Prior to joining Tokai, Mr. McBride founded and served as President of Alliance Life Science Advisors, Inc., a consulting firm focused on assisting life science companies with strategic planning, business development and financing projects, where Mr. McBride was active from March 2012 until February 2014 and became active again beginning in June 2017 until August 2019. Prior to founding Alliance Life Science Advisors, Inc., Mr. McBride was an independent consultant from January 2009 until March 2012. In addition, Mr. McBride previously served as Executive Vice President and Chief Operating Officer of Gloucester Pharmaceuticals, Inc., Global Head of Oncology Licensing at Pharmacia Corporation, Executive Vice President, Business Operations and Chief Financial Officer at CytoTherapeutics, Inc., Vice President, Business Development and Treasurer at Phytera, Inc., Vice President, Commercial Development at Sparta Pharmaceuticals, Inc. and Vice President, Business Development at U.S. Bioscience, Inc..
As the Director of Novus Therapeutics Inc, the total compensation of John McBride at Novus Therapeutics Inc is $647,278. There are no executives at Novus Therapeutics Inc getting paid more.
John McBride is 67, he's been the Director of Novus Therapeutics Inc since 2017. There are 1 older and 4 younger executives at Novus Therapeutics Inc. The oldest executive at Novus Therapeutics Inc is Gary Lyons, 68, who is the Independent Director.
John's mailing address filed with the SEC is C/O NOVUS THERAPEUTICS, INC., 19900 MACARTHUR BLVD., SUITE 550, IRVINE, CA, 92612.
Over the last 7 years, insiders at Novus Therapeutics Inc have traded over $2,287,089 worth of Novus Therapeutics Inc stock and bought 1,499,013 units worth $7,312,148 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Israel Gp Ltd.Orbi Med Isra... és Erez Chimovits. On average, Novus Therapeutics Inc executives and independent directors trade stock every 100 days with the average trade being worth of $1,832,709. The most recent stock trade was executed by Israel Gp Ltd.Orbi Med Isra... on 2 December 2020, trading 103,200 units of NVUS stock currently worth $2,229,120.
Novus Therapeutics Inc executives and other stock owners filed with the SEC include: